Literature DB >> 2898602

Severe hypocalcaemia in AIDS patients treated with foscarnet and pentamidine.

M S Youle, J Clarbour, B Gazzard, A Chanas.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2898602     DOI: 10.1016/s0140-6736(88)92260-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

Review 1.  Practical advice for the gastroenterologist dealing with symptomatic HIV disease.

Authors:  B G Gazzard
Journal:  Gut       Date:  1990-07       Impact factor: 23.059

2.  Disorders of serum calcium in acquired immunodeficiency syndrome.

Authors:  S A Peter
Journal:  J Natl Med Assoc       Date:  1992-07       Impact factor: 1.798

Review 3.  Comparative tolerability of therapies for cytomegalovirus retinitis.

Authors:  S Walmsley; A Tseng
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

Review 4.  Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.

Authors:  P Chrisp; S P Clissold
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

Review 5.  Minimising the dosage-limiting toxicities of foscarnet induction therapy.

Authors:  D T Jayaweera
Journal:  Drug Saf       Date:  1997-04       Impact factor: 5.606

6.  Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet.

Authors:  R F Omar; N Dusserre; A Désormeaux; L Poulin; M Tremblay; D Beauchamp; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 7.  Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

8.  Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART).

Authors:  J Teichmann; U Lange; T Discher; J Lohmeyer; H Stracke; R G Bretzel
Journal:  Eur J Med Res       Date:  2009       Impact factor: 2.175

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.